Bavarian Nordic Aims To Advance Early-Stage Pipeline With Funds From Bristol Deal
This article was originally published in The Pink Sheet Daily
By buying an option to license and commercialize Bavarian Nordic’s Prostvac, Bristol-Myers Squibb will be validating the drug’s underlying technology and providing the Danish biotech needed cash to progress its remaining pipeline.
You may also be interested in...
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.